Revolutionizing Dry Eye Treatment

We are a clinical-stage dry eye company with a first-of-a-kind patented technology that enables existing drugs to act through unique neural pathways.

Introducing Pro-ocular™

Our Breakthrough Therapy for Treating Dry Eye Disease (DED) Without The Hassle Of Eye Drop Instillation

A NON-EYE DROP APPROACH

No need to use messy, difficult to instill eye drops that often cause blurry vision, red eyes and burning and stinging.

TRANSAPPENDAGEAL APPLICATION*

Our odorless, colorless, aqueous gel is applied across the forehead, using the trigeminal nerve to stimulate natural, non-irritating tear production and reduce inflammation and pain.

*(Drug delivery via hair follicles or sweat glands in the skin)

EASE OF USE

Twice daily forehead application reduces annual applications by over 700 compared to twice-daily eye drops and over 2,150 compared to four times a day eye drops.

Patents Secured

Countries Convered

Addressing a Critical Need

Widespread Issue
DED affects 38 million people in the U.S., with 18 million diagnosed cases.
Better Compliance
Current eye drop and nasal treatments often fall short, leading to user dissatisfaction. Pro-ocular offers an easy to use solution with superior patient compliance and results.

Proven Results

In three Phase 2 studies, Pro-ocular™ showed statistically significant improvements across all severities of DED.

With a quick onset of action in two weeks or less, 61% of patients continued using Pro-ocular™ after two years, and 48% continued use after 2.8 years.

Join Our Mission

Signal12 is raising capital to complete Phase 3 trials and bring Pro-ocular to market. Invest in a future where dry eye sufferers can enjoy lasting relief and improved vision.

Pro-ocular™
Clinical Trials
Company
Leadership

Signal12 Inc.

Signal12 is a clinical-stage dry eye company that develops novel therapies to address ophthalmic diseases. Through three Phase 2 clinical studies, the company’s proprietary topical drug, Pro-ocular™ has demonstrated efficacy in safely and effectively reducing the signs and symptoms of dry eye disease (DED). Pro-ocular™ is the first product for DED to utilize transappendageal delivery, and the only product to treat DED by targeting the ophthalmic branch of the trigeminal nerve. The company has offices in Greenwich, CT and Boston, MA.

Signal12 is actively raising capital to complete Phase 3 clinical trials and bring Pro-ocular™ to market. For information on investment opportunities, please email Neil Edwards at [email protected].